The Week In... Pharma (03-07/12)
  • Posted on: 07/12/2018
  • Category: Industry

The Week In... Pharma (03-07/12)

No time to browse? Here’s what’s hitting the pharma headlines this week! Top stories in the first week of December include GSK announcing their acquisition of a US Oncology firm, UK pharma pressing ahead with deals despite Brexit uncertainty, and the UK’s first dedicated Vaccines Manufacturing Innovation Centre is announced. Take a look -

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Head of Business Development, Ryan Wooller, at, or get in touch on 07748 464 079.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

UK to pursue deals and acquisitions despite Brexit uncertainty

The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.

Industrial strategy delivers new vaccines manufacturing centre to lead the fight against deadly disease

The UK’s first-ever dedicated Vaccines Manufacturing Innovation Centre will ensure the UK life sciences industry remains at the forefront of worldwide efforts to tackle life-threatening diseases, including Ebola.

GlaxoSmithKline Acquires US Oncology Firm, Sells Horlicks Unit

GlaxoSmithKline PLC on Monday announced it will pay USD5.1 billion for oncology-focused US pharma company Tesaro Inc and sell its Indian nutrition brands to Unilever PLC.

Despite innovation, Europeans wait years for new cancer drugs

Rapid advances in cancer science have increased the number of new oncology drugs being developed, but delays in regulation and approvals mean patients in Europe often wait years to be able to access them, researchers said on Tuesday.

UK-funded study to investigate patients’ experience of cell and gene therapies

Innovate UK is helping to fund the PROmics study, a programme designed to assess the effect of cell therapies on patient symptoms and quality of life.

While you’re here…

…and are interested in our content, why not sign up to our newsletter? It’s just below here.